National Institutes of Health: Zika Virus Infection trials

The registry lists 13 Zika Virus Infection studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 8Phase 2 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsRecruitingNCT01386424
• Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)CompletedNCT05123222Phase 1Results posted
• Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve AdultsCompletedNCT03611946Phase 1Results posted
• VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and AdolescentsCompletedNCT03110770Phase 2Results posted
• Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic AreaCompletedNCT03008122Phase 1Results posted
• Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP ChallengeCompletedNCT06805487Phase 1
• A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)CompletedNCT04514107Not applicable
• Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in ChildrenCompletedNCT03534245
• VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy AdultsCompletedNCT02996461Phase 1
• A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.CompletedNCT02963909Phase 1
• ZIKA Vaccine in Naive SubjectsCompletedNCT02952833Phase 1
• Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy AdultsCompletedNCT02840487Phase 1
• Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)CompletedNCT02794181